Immunotherapy or chemo pills after chemoradiation for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial compares two options—a type of immunotherapy or a chemotherapy pill (capecitabine)—as maintenance treatment after standard chemoradiation for high-risk nasopharyngeal cancer. It aims to see which helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal cancer that is not the keratinizing type (your doctor will know).
- Your cancer is stage III OR you had a high level of Epstein-Barr virus DNA in your blood before treatment.
- You have already received 3 cycles of induction immunochemotherapy and your tumor has shrunk (complete or partial response) confirmed by a scope and MRI.
- You are between 18 and 70 years old.
- You have good overall health (ECOG score 0 or 1) and your kidney, liver, and blood counts are within acceptable ranges.
- You have not had prior radiation or chemotherapy for this cancer, no prior checkpoint inhibitor therapy, and no uncontrolled autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial tests whether adding an extra treatment after standard chemoradiation can reduce the chance of nasopharyngeal cancer coming back. The new treatment combines an immunotherapy drug (sintilimab) with a chemotherapy pill (capecitabine) for a year.
Hear when a new Nasopharangeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.